Shares of Amgen Inc. AMGN shed 2.39% to $306.86 Tuesday, on what proved to be an all-around favorable trading session for the ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 19 unusual trades. Delving into the details, we found 26% of ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...